Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

Vaccine

Volumn 32, Issue 1, 2013, Pages 26-32

  Mesher, D ^a   Soldan, K ^a   Howell Jones, R ^a   Panwar, K ^a   Manyenga, P ^a   Jit, M ^a   Beddows, S ^a   Gill, O N ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Cervarix; HPV immunisation; HPV prevalence; Surveillance

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIA; CHLAMYDIASIS; COMMUNITY CARE; CONTROLLED STUDY; DRUG EFFICACY; FAMILY PLANNING; FEMALE; GENOTYPE; GROUPS BY AGE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; LABORATORY; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SCREENING TEST; SEXUAL BEHAVIOR; UNITED KINGDOM; VAGINA SMEAR; VULVA VAGINAL SWAB; YOUNG ADULT;

CERVARIX; CI; CONFIDENCE INTERVAL; GENERAL PRACTICE; GP; HC2; HIGH-RISK; HPV; HPV IMMUNISATION; HPV PREVALENCE; HR; HUMAN PAPILLOMAVIRUS; HYBRID CAPTURE 2; LA; LINEAR ARRAY; LOW-RISK; LOWER SUPER OUTPUT AREA; LR; LSOA; NATIONAL CHLAMYDIA SCREENING PROGRAMME; NCSP; ODDS RATIO; OR; PCR; PCT; PDH; PHE; POLYMERASE CHAIN REACTION; PRIMARY CARE TRUST; PUBLIC HEALTH ENGLAND; PYRUVATE DEHYDROGENASE; REC; RESEARCH ETHICS COMMITTEE; SURVEILLANCE; VULVA-VAGINAL SWAB; VVS;

ADOLESCENT; ADULT; AGE FACTORS; ENGLAND; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; SEXUAL BEHAVIOR; VACCINATION; YOUNG ADULT;

EID: 84891957968     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.085     Document Type: Article

References (27)

1. De Carvalho N., Teixeira J., Roteli-Martins C.M., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
2. Lehtinen M., Paavonen J., Wheeler C.M., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011.
3. Dillner J., Kjaer S.K., Wheeler C.M., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
4. World Health Organization, Number of countries having introduced HPV vaccines to date, Available from (accessed September 2012). http://www.who.int/nuvi/hpv/decision_implementation/en/index.html.
5. Department of Health, Annual HPV vaccine uptake in England: 2010/11, Available from URL: (accessed October 2012). https://www.wp.dh.gov.uk/immunisation/files/2012/03/120319_HPV_UptakeReport2010-11-revised_acc.pdf.
6. National Chlamydia Screening Programme, National Chlamydia Screening Programme Standards, sixth ed., Available from URL: (accessed June 2013). http://www.chlamydiascreening.nhs.uk/ps/resources/core-requirements/NCSP%20Standards%20Edition%206_Accompanying%20Information%20Document_October%202012.pdf.
7. Howell-Jones R., de Silva N., Akpan M., et al. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012, 30:3867-3875.
8. Bissett S.L., Howell-Jones R., Swift C., et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 2011, 83:1744-1751.
9. Bouvard V., Baan R., Straif K., et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 2009, 10:321-322.
10. Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008, 46:2595-2604.
11. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367.
12. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
13. Castle P.E., Rodriguez A.C., Porras C., et al. A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007, 34:849-855.
14. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
15. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
16. Byington C.L., Samore M.H., Stoddard G.J., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21-29.
17. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. PNAS 1997, 94:6571-6576.
18. Durham D.P., Poolman E.M., Ibuka Y., Townsend J.P., Galvani A.P. Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types. J Infect Dis 2012, 206:1291-1298.
19. Cuschieri K., Kavanagh K., Sinka K., et al. Effect of HPV assay choice on perceived prevalence in a population-based sample. Diagn Mol Pathol 2013, 22:85-90.
20. van Alewijk D., Kleter B., Vent M., et al. An HPV testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR and a novel E6 high-risk multiplex type-specific genotyping PCR. J Clin Microbiol 2013.
21. Mori S., Nakao S., Kukimoto I., Kusumoto-Matsuo R., Kondo K., Kanda T. Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 2011, 102:1223-1227.
22. Van Doorn L.J., Molijn A., Kleter B., Quint W., Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44:3292-3298.
23. Schmitt M., Dondog B., Waterboer T., Pawlita M., Tommasino M., Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010, 48:143-149.
24. Eklund C., Zhou T., Dillner J. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010, 48:4147-4155.
25. Riha J., Mercer C.H., Soldan K., French C.E., Macintosh M. Who is being tested by the English National Chlamydia Screening Programme? A comparison with national probability survey data. Sex Transm Infect 2011, 87:306-311.
26. Tabrizi S.N., Brotherton J.M., Kaldor J.M., et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206:1645-1651.
27. Markowitz L.E., Hariri S., Lin C., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, national health and nutrition examination surveys, 2003-2010. J Infect Dis 2013, 208:385-393.